MedPath

Recombinant Human Granulocyte/Macrophage Colonystimulating Factor(rhGM-CSF)

Generic Name
Recombinant Human Granulocyte/Macrophage Colonystimulating Factor(rhGM-CSF)
Brand Names
-
Drug Type
-
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Indication

用于:1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染;

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥;

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员;

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少;

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Associated Conditions
-
Associated Therapies
-

The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy

Phase 2
Recruiting
Conditions
GM-CSF
Interventions
First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
138
Registration Number
NCT06472739
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Phase 2
Recruiting
Conditions
Neuroblastoma
Interventions
Drug: Universal Donor (UD) TGFβi NK Cells
Drug: Temozolomide
Drug: Irinotecan
Drug: Dinutuximab
Drug: GM-CSF
First Posted Date
2024-06-10
Last Posted Date
2024-12-19
Lead Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Target Recruit Count
62
Registration Number
NCT06450041
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

UCSF Benioff Children's Hospital, San Francisco, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

and more 10 locations

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

First Posted Date
2023-08-28
Last Posted Date
2023-09-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
30
Registration Number
NCT06013618
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Phase 2
Recruiting
Conditions
Advanced Solid Tumor
Refractory Tumor
Interventions
Drug: Thymalfasin
Radiation: Radiotherapy
Drug: PD-1/PD-L1 inhibitor
Drug: GM-CSF
First Posted Date
2023-03-30
Last Posted Date
2023-03-30
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
60
Registration Number
NCT05790447
Locations
🇨🇳

The Second Affiliated Hospital of SchoowUniversity, Suzhou, China

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Phase 2
Recruiting
Conditions
Objective Response Rate
Interventions
First Posted Date
2023-03-08
Last Posted Date
2023-03-08
Lead Sponsor
Xiangpan Li
Target Recruit Count
56
Registration Number
NCT05760196
Locations
🇨🇳

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Phase 2
Not yet recruiting
Conditions
Carcinoma Breast
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Vinorelbine
Radiation: Radiotherapy
Drug: PD-1/PD-L1 inhibitor
Drug: GM-CSF
Drug: IL-2
First Posted Date
2022-11-02
Last Posted Date
2022-11-02
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
45
Registration Number
NCT05603013
Locations
🇨🇳

Second Affiliated Hospital of Soochow University, Suzhou, China

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Phase 2
Not yet recruiting
Conditions
Metastatic Solid Tumor
Interventions
Radiation: Hypofractionated radiotherapy
Drug: PD-L1 inhibitor
Drug: GM-CSF
Drug: IL-2
First Posted Date
2022-09-07
Last Posted Date
2022-09-07
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
56
Registration Number
NCT05530200

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Phase 2
Not yet recruiting
Conditions
Glioma, Malignant
Interventions
First Posted Date
2022-05-09
Last Posted Date
2022-05-13
Lead Sponsor
Epitopoietic Research Corporation
Target Recruit Count
28
Registration Number
NCT05366062
Locations
🇹🇭

Bumrungrad International Hospital, Bangkok, Vadhana, Thailand

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Phase 1
Recruiting
Conditions
Resectable Esophageal Cancer
Interventions
Biological: iNeo-Vac-P01
Biological: GM-CSF
First Posted Date
2022-04-01
Last Posted Date
2024-11-21
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
40
Registration Number
NCT05307835
Locations
🇨🇳

The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

Radiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRC

Phase 2
Conditions
Colorectal Neoplasms
Interventions
Radiation: hypofractionation Radiotherapy
Drug: sintilimab
Drug: GM-CSF
Drug: Fruquintinib
First Posted Date
2022-03-23
Last Posted Date
2022-03-31
Lead Sponsor
The First Affiliated Hospital of Xiamen University
Target Recruit Count
71
Registration Number
NCT05292417
Locations
🇨🇳

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath